Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance.
OBJECTIVE
Idiopathic orthostatic intolerance (IOI) is a common disorder that is characterized by chronic orthostatic symptoms and substantial increases in heart rate and plasma norepinephrine concentrations that are disproportionately high while standing. Several features of the syndrome, including the tachycardia, tremulousness, and exaggerated norepinephrine have been considered potentially due to hypoactive or hyperactive states of adrenergic receptors of the sympathetic nervous system. The aim of this study was therefore to ascertain whether genotypes at eight polymorphic loci within five relevant adrenergic receptor genes (alpha2A, alpha2B, alpha2C, beta1 and beta2) influence the risk for IOI.


METHODS
We studied 80 young men in military service (20 patients with IOI and 60 age-matched controls). All participants underwent a tilt table test including monitoring of blood pressure, heart rate and plasma catecholamines, in the supine position and during 30 min of standing. Genotyping at the eight loci (alpha2ALys251, alpha2BDel301-303, alpha2CDel322-325, beta1Gly49, beta1Arg389, beta2Arg16, beta2Glu27, beta2Ile164) was performed in all participants. Chi-square tests of independence were used to test for associations between IOI and genotype. In addition, an association of the polymorphisms with haemodynamic variables (heart rate, supine and upright blood pressure) was ascertained using one-way variance analysis.


RESULTS
For the beta1Gly49 polymorphism we found a decrease in the risk of IOI among persons who were homozygous (odds ratio, 0.88; 95% confidence interval, 0.81-0.97). In addition, we found an association between beta1Gly49 and decreased heart rate in the upright position, regardless of IOI diagnosis. There were no associations with the other studied polymorphisms and IOI.


CONCLUSIONS
Our current results suggest that the beta1Gly49 polymorphism is protective for IOI. This is likely one of several common genetic loci that may represent modifiers of IOI phenotypes.
Winker
R
R
Division of Occupational Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. robert.winker@meduniwien.ac.at
Barth
A
A
Valic
E
E
Maier
R
R
Osterode
W
W
Pilger
A
A
Rüdiger
H W
HW
D000293:Adolescent; D000328:Adult; D001317:Austria; D016022:Case-Control Studies; D005838:Genotype; D006439:Hemodynamics; D006801:Humans; D007024:Hypotension, Orthostatic / Q000209:etiology* / Q000235:genetics / Q000503:physiopathology; D008297:Male; D008889:Military Personnel; D009638:Norepinephrine / Q000097:blood; D011110:Polymorphism, Genetic; D011941:Receptors, Adrenergic / Q000145:classification / Q000235:genetics*; D018570:Risk Assessment
D011941:Receptors, Adrenergic; D009638:Norepinephrine
J Biol Chem. 1999 Apr 30;274(18):12670-4
10212248
Trends Pharmacol Sci. 2001 Sep;22(9):471-7
11543875
Circulation. 2000 Jun 27;101(25):2877-82
10869257
J Biol Chem. 2001 Feb 16;276(7):4917-22
11056163
Am Heart J. 2002 Nov;144(5):840-6
12422153
J Clin Invest. 1998 Oct 15;102(8):1534-9
9788966
J Biol Chem. 2000 Jul 28;275(30):23059-64
10801795
J Cardiovasc Pharmacol. 2002 Feb;39(2):155-60
11791000
N Engl J Med. 2002 Oct 10;347(15):1135-42
12374873
N Engl J Med. 2001 Oct 4;345(14):1030-5
11586955
Am J Med Sci. 1999 Feb;317(2):88-101
10037112
Clin Sci (Lond). 2002 Nov;103(5):517-24
12401126
N Engl J Med. 2000 Feb 24;342(8):541-9
10684912
Circulation. 2000 Dec 19;102(25):3086-91
11120699
Hypertension. 2002 Jan;39(1):173-8
11799098
Chest. 1996 Jun;109(6):1636-42
8769523
Int Arch Occup Environ Health. 2003 Mar;76(2):143-50
12733087
Am J Hum Genet. 2002 Apr;70(4):935-42
11854867
Annu Rev Pharmacol Toxicol. 2003;43:381-411
12540746
Biochemistry. 1994 Aug 16;33(32):9414-9
7915137
Br J Pharmacol. 1996 Jul;118(6):1403-8
8832064
Circ Res. 2000 Apr 28;86(8):834-40
10785504
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10483-8
10984540
Pacing Clin Electrophysiol. 2003 Apr;26(4 Pt 1):892-901
12715851
Am Heart J. 2000 Mar;139(3):537-42
10689270
Methods Enzymol. 2002;343:459-75
11665585
Br J Pharmacol. 1998 Feb;123(4):701-11
9517390
Clin Pharmacol Ther. 2003 Jul;74(1):44-52
12844134
Circulation. 2001 Feb 27;103(8):1048-50
11222464
Am J Med Sci. 1999 Nov;318(5):298-303
10555091
Nat Med. 2003 Oct;9(10):1300-5
14502278
J Biol Chem. 2000 Dec 8;275(49):38518-23
10948191
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10483-8
8816827
J Biol Chem. 1993 Nov 5;268(31):23116-21
7901205
Comput Biol Med. 1998 Mar;28(2):121-42
9684089